Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P440: Comparison of infliximab serum levels between venous and capillary blood in paediatric IBD patients using novel blood sampling technology

ECCO '19 Copenhagen

Year: 2019
Authors:

M. Zijlstra*1, M. Jongsma2, A. de Vries3, T. Schaap3, K. Bloem3, L. de Ridder2

1Wilhelmina Children's Hospital, Pediatric Gastro-enterology, Utrecht, The Netherlands, 2Erasmus MC-Sophia, Pediatric Gastro-enterology, Rotterdam, The Netherlands, 3Sanquin Diagnostic Services, Biologics Lab, Amsterdam, The Netherlands

P441: Long-term immunogenicity of vedolizumab in ulcerative colitis and Crohn’s disease (GEMINI Programme)

ECCO '19 Copenhagen

Year: 2019
Authors:

T. Wyant1, L. Yang2, R. Lirio2, M. Rosario*2

1Abpro Corp., Woburn, USA, 2Takeda Pharmaceuticals, Cambridge, USA

P442: Strictureplasty for Crohn’s disease of the small bowel in the biological era: long-term outcomes and risk factors for site specific recurrence

ECCO '19 Copenhagen

Year: 2019
Authors:

M. Rottoli*1, C. A. Manzo1, M. Tanzanu1, F. Rizzello1, P. Gionchetti1, G. Poggioli1

1Sant'Orsola Hospital, Alma Mater Studiorum University of Bologna, Department of Medical and Surgical Sciences, Bologna, Italy

P443: Clinical features, therapeutic requirements, and evolution of patients with Crohn's disease and upper digestive tract involvement (CROHNEX study)

ECCO '19 Copenhagen

Year: 2019
Authors:

E. Sainz Arnau*1, Y. Zabana2, I. Miguel3, A. Fernández Clotet4, M. J. Casanova5, M. D. Martín6, M. D. Picó7, E. Alfambra8, I. Rodriguez9, F. Muñoz10, M. Domínguez11, E. Iglesias12, D. Busquets13, A. Gutiérrez14, F. Cañete15, L. Nuñez16, C. Taxonera17, B. Beltrán18, B. Camps19, X. Calvet20, P. Navarro21, M. Calafat22, R. Ferreiro-Iglesias23, C. González-Muñoza24, B. Sicilia25, C. Rodríguez26, A. Y. Carbajo27, M. van Domselaar28, R. Vicente29, M. Piqueras30, M. C. Muñoz31, À. Abad32, A. Algaba33, P. Martínez34, M. I. Vela35, B. Antolín36, J. M. Huguet37, L. Bujanda38, R. H. Lorente39, P. Almela40, M. J. García41, P. Ramírez de la Piscina42, R. Pajares43, I. Pérez-Martínez44, A. J. Lucendo45, O. Merino46, J. Legido47, I. Vera48, V. J. Morales49, M. Esteve2

1Hospital Sant Joan de Déu Althaia - Manresa, Gastroenterology, Manresa- Barcelona, Spain, 2Hospital Mútua de Terrassa, Gastroenterology, Terrassa- Barcelona, Spain, 3Hospital Arnau de Vilanova, Gastroenterology, Lleida, Spain, 4Hospital Clínic de Barcelona, Gastroenterology, Barcelona, Spain, 5Hospital Universitario de la Princesa, Gastroenterology, Madrid, Spain, 6Hospital La Paz, Gastroenterology, Madrid, Spain, 7HGU de Elche, Gastroenterology, Elche- Alicante, Spain, 8Hospital Clínico Universitario Lozano Blesa, Gastroenterology, Zaragoza, Spain, 9Hospital de Galdakao, Gastroenterology, Galdakao-Vizcaya, Spain, 10HU Salamanca, Gastroenterology, Salamanca, Spain, 11Hospital San Jorge, Gastroenterology, Huesca, Spain, 12Hospital Reina Sofía, Gastroenterology, Córdoba, Spain, 13Hospital dr. Josep Trueta, Gastroenterology, Girona, Spain, 14HGU Alicante, Gastroenterology, Alicante, Spain, 15Hospital Germans Trias i Pujol, Gastroenterology, Barcelona, Spain, 16Hospital Ramón y Cajal, Gastroenterology, Madrid, Spain, 17Hospital Clínico San Carlos, Gastroenterology, Madrid, Spain, 18Hospital La Fe, Gastroenterology, Valencia, Spain, 19Hospital de Bellvitge, Gastroenterology, Barcelona, Spain, 20Hospital Parc Taulí, Gastroenterology, Sabadell-Barcelona, Spain, 21Hospital Clínico, Gastroenterology, Valencia, Spain, 22Hospital Son Llàtzer, Gastroenterology, Mallorca, Spain, 23Hospital de Santiago, Gastroenterology, Santiago de Compostela, Spain, 24Hospital de la Santa Creu i Sant Pau, Gastroenterology, Barcelona, Spain, 25Complejo Hospitalario de Burgos, Gastroenterology, Burgos, Spain, 26Complejo Hospitalario de Navarra, Gastroenterology, Pamplona, Spain, 27Hospital Río Hortega, Gastroenterology, Valladolid, Spain, 28Hospital de Torrejón, Gastroenterology, Torrrejón-Madrid, Spain, 29HU Miguel Servet, Gastroenterology, Zaragoza, Spain, 30Consorci Sanitari Mútua de Terrassa, Gastroenterology, Terrassa-Barcelona, Spain, 31Hospital de Basurto, Gastroenterology, Basurto-Bilbao, Spain, 32Hospital Viladecans, Gastroenterology, Viladecans-Barcelona, Spain, 33HU de Fuenlabrada, Gastroenterology, Fuenlabrada-Madrid, Spain, 34Hospital 12 de Octubre, Gastroenterology, Madrid, Spain, 35Hospital Nuestra Señora de la Candelaria, Gastroenterology, Santa Cruz de Tenerife, Spain, 36Hospital Clínico, Gastroenterology, Valladolid, Spain, 37Hospital General Universitario, Gastroenterology, Valencia, Spain, 38Hospital de Donostia, Gastroenterology, Donostia, Spain, 39Hospital General, Gastroenterology, Ciudad Real, Spain, 40Hospital General, Gastroenterology, Castelló, Spain, 41Hospital Marqués de Valdecilla, Gastroenterology, Santander, Spain, 42HU de Álava, Gastroenterology, Álava, Spain, 43Hospital Infanta Sofía, Gastroenterology, Madrid, Spain, 44HU Central de Asturias, Gastroenterology, Oviedo, Spain, 45Hospital General de Tomelloso, Gastroenterology, Tomelloso-Ciudad Real, Spain, 46Hospital de Cruces, Gastroenterology, Barakaldo-Bilbao, Spain, 47Hospital de Segovia, Gastroenterology, Segovia, Spain, 48HU Puerta de Hierro, Gastroenterology, Majadahonda-Madrid, Spain, 49Hospital General de Granollers, Gastroenterology, Granollers-Barcelona, Spain

P444: Post-induction Infliximab trough levels in severe and moderate paediatric ulcerative colitis: preliminary data of a retrospective, population cohort-based study

ECCO '19 Copenhagen

Year: 2019
Authors:

M. Martinelli*1,2, H. Moore2, N. Devas2, A. Galgano2, R. N. Baldassano2

1University of Naples, Translational Medical Science, Section of Pediatrics, Naples, Italy, 2Children Hospital of Philadelphia, Gastroenterology, Hepatology and Nutrition Division, Philadelphia, USA

P445: Prevalence rates of biosimilar discontinuation and switchback to originator biologics following non-medical switching: a meta-analysis of real-world studies

ECCO '19 Copenhagen

Year: 2019
Authors:

L. Yifei*1, M. Skup2, M. Yang3, C. Qi3, T. Doctor3

1University of Missouri – Kansas City School of Pharmacy, Kansas City, USA, 2AbbVie, Chicago, USA, 3Analysis Group, Boston, USA

P446: Dose escalation with originator infliximab is more common than standard dosing in paediatric IBD: the DEVELOP experience

ECCO '19 Copenhagen

Year: 2019
Authors:

J. Escher*1, M. Dubinsky2, J. Izanec3, C. Busse3, Y. Wang4, A. Griffiths5

1Erasmus Mc-Sophia Children's Hospital, Rotterdam, The Netherlands, 2Icahn School of Medicine, Mount Sinai, New York, USA, 3Janssen Scientific Affairs, LLC, Horsham, USA, 4Janssen Research and Development, LLC, Spring House, USA, 5The Hospital for Sick Children, University of Toronto, Toronto, Canada

P447: The impact of therapeutic drug monitoring during biosimilar infliximab switch in inflammatory bowel disease

ECCO '19 Copenhagen

Year: 2019
Authors:

R. Ranjan*1, S. Myers2, L. Crissop1, S. Ritchie1, F. Maw1, S. Sebastian2, A. Dhar1

1County Durham and Darlington NHS Foundation Trust, Gastroenterology, Durham, UK, 2Hull Royal Infirmary, Gastroenterology, Hull, UK

P448: Cannabis and cannabinoids for the treatment of inflammatory bowel disease: a systematic review and meta-analysis

ECCO '19 Copenhagen

Year: 2019
Authors:

B. Doeve1, F. van Schaik*1, M. van de Meeberg1, H. Fidder1

1University Medical Center Utrecht, Utrecht, The Netherlands

P449: Selective depletion of LAG3+ cells in T-cell-driven inflammation: a randomised, double-blind, placebo-controlled, FTIH phase I/Ib clinical trial

ECCO '19 Copenhagen

Year: 2019
Authors:

J. Ellis1, D. Marks*1, C. Barrett1, T. Hopkins1, A. Richards1, R. Fuhr2, M. Albayaty3, M. Coenen4, L. Liefaard5, K. Leavens1, K. Nevin1, S. Tang6, S. Hughes1, N. Srinivasan1, K. Edwards5, R. Anselm5, T. Schmidt7, J. Stone8, C. Savage1, N. Wisniacki1, R. Tarzi1

1GlaxoSmithKline, Clinical Pharmacology and Experimental Medicine, Stevenage, UK, 2PAREXEL International, Berlin, Germany, 3PAREXEL International, London, UK, 4Institute of Clinical Chemistry and Clinical Pharmacology, Study Center Bonn (SZB), Bonn, Germany, 5GlaxoSmithKline, Stevenage, UK, 6GlaxoSmithKline, Upper Providence, USA, 7TxCell S.A., Valbonne, France, 8IMED Biotech, AstraZeneca, Cambridge, UK

P450: Association of Infliximab trough levels and transmural healing in Crohn’s disease

ECCO '19 Copenhagen

Year: 2019
Authors:

S. Bernardo*1, S. Fernandes1, C. Simões1, A. R. Gonçalves1, C. Baldaia1, A. Valente1, P. Moura Santos1, L. Correia1, R. Marinho1

1Hospital Santa Maria, CHLN, Gastrenterology, Lisbon, Portugal

P451: Safety and efficacy of ferric carboxymaltose (FCM) for the treatment of iron deficiency anaemia in paediatric patients affected by inflammatory bowel disease (pIBD)

ECCO '19 Copenhagen

Year: 2019
Authors:

L. Cococcioni*1, A. Elzein1, S. Sider1, S. Chadokufa1, R. Buckingham1, A. Ocholi1, N. Shah1, S. McCartney2, E. Saliakellis1, O. Borrelli1, F. Kiparissi1

1Great Ormond Street Hospital, Gastroenterology, London, UK, 2University College London Hospital, Gastroenterology, London, UK

P452: Impact of implementing a rapid access clinic in a high-volume inflammatory bowel disease centre: accessibility, resource utilisation and outcomes

ECCO '19 Copenhagen

Year: 2019
Authors:

J. Reinglas*1, S. Nene1, L. Gonczi2, Z. Kurti2, S. Restellini3, R. Kohen1, W. Afif1, T. Bessissow1, G. Wild1, E. Seidman1, A. Bitton1, P. Lakatos1

1McGill University Health Center, Division of Gastroenterology, Montreal, Canada, 2Semmelweis University, First Department of Internal Medicine, Budapest, Hungary, 3Geneva’s University Hospitals and University of Geneva, Division of Gastroenterology and Hepatology, Geneva, Switzerland

P453: Golimumab in real-world practice in patients with ulcerative colitis: 2-year interim results from a non-interventional trial in Germany

ECCO '19 Copenhagen

Year: 2019
Authors:

N. Teich1, H. Gruemmer2, E. Joergensen3, T. Liceni4, W. Holtkamp-Endemann5, F. Cornillie6, S. Hohenberger7, T. Fischer*7

1Internistische Gemeinschaftspraxis für Verdauungs- und Stoffwechselkrankheiten Leipzig und Schkeuditz, Leipzig, Germany, 2Praxis Gruemmer, Potsdam, Germany, 3Magen Darm Zentrum, Remscheid, Germany, 4MVZ für Gastroenterologie am Bayerischen Platz, Berlin, Germany, 5Gastroenterologische Gemeinschaftspraxis am Germania-Campus, Muenster, Germany, 6MSD Merck Sharp and Dohme AG, Global Medical Affairs, Kriens, Switzerland, 7MSD Sharp and Dohme GmbH, Medical Affairs, Haar, Germany

P454: Prediction of endoscopic activity in patients with Crohn’s disease: systematic review and external validation of published prediction models

ECCO '19 Copenhagen

Year: 2019
Authors:

E. C. Brand*1,2, S. G. Elias3, I. M. Minderhoud4, J. J. van der Veen1, F. Baert5, D. Laharie6, P. Bossuyt7, Y. Bouhnik8, A. Buisson9, G. Lambrecht10, E. Louis11, B. Pariente12, M. J. Pierik13, C. J. van der Woude14, G. R. D'Haens15, S. Vermeire16, B. Oldenburg1

1University Medical Centre Utrecht, Department of Gastroenterology and Hepatology, Utrecht, The Netherlands, 2University Medical Centre Utrecht, Laboratory for Translational Immunology, Utrecht, The Netherlands, 3University Medical Centre Utrecht, Julius Centre for Health Sciences and Primary Care, Utrecht, The Netherlands, 4Tergooi hospitals, Department of Gastroenterology and Hepatology, Blaricum/Hilversum, The Netherlands, 5AZ Delta, Department of Gastroenterology, Roeselare, Belgium, 6Hôpital Haut-Lévêque, Service d'Hépato-gastroentérologie et Oncologie Digestive, Bordeaux, France, 7Imelda General Hospital, IBD Clinic, Bonheiden, Belgium, 8Beaujon Hospital, APHP, Paris Diderot University, Department of Gastroenterology, Clichy, France, 9Estaing University Hospital, Department of Gastroenterology, Clermont-Ferrand, France, 10AZ Damiaan, Department of Gastroenterology, Oostende, Belgium, 11Liège University Hospital CHU, Department of Gastroenterology, Liège, Belgium, 12Huriez Hospital, Lille 2 University, Department of Gastroenterology, Lille, France, 13Maastricht University Medical Centre, Department of Gastroenterology and Hepatology, Maastricht, The Netherlands, 14Erasmus Medical Centre, Department of Gastroenterology and Hepatology, Rotterdam, The Netherlands, 15Amsterdam UMC, University of Amsterdam, Department of Gastroenterology, Amsterdam, The Netherlands, 16University Hospitals Leuven, Department of Gastroenterology and Hepathology, Leuven, Belgium

P455: Evaluation of the optic nerve function in patients with ulcerative colitis and Crohn’s disease

ECCO '19 Copenhagen

Year: 2019
Authors:

A. Skamnelos*1, A. Kavvadias1, P. Zafeiropoulos2, K. Katsanos1, I. Asproudis2, D. Christodoulou1

1University Hospital of Ioannina, Division of Gastroenterology, Ioannnina, Greece, 2University Hospital of Ioannina, Universital Eye Clinic, Ioannnina, Greece

P456: Quality of life is associated with wearable-based physical activity in patients with inflammatory bowel disease: a prospective, observational study

ECCO '19 Copenhagen

Year: 2019
Authors:

M. Wiestler*1, F. Kockelmann1, M. Kück2, A. Kerling2, U. Tegtbur2, M. P. Manns1, M. Attaran-Bandarabadi1, O. Bachmann1

1Hannover Medical School (MHH), Gastroenterology, Hepatology and Endocrinology, Hannover, Germany, 2Hannover Medical School (MHH), Institute for Sports Medicine, Hannover, Germany

P457: Influence of concomitant immunomodulators during maintenance therapy with Adalimumab in inflammatory bowel disease: looking for the ideal patient to use monotherapy

ECCO '19 Copenhagen

Year: 2019
Authors:

G. Bastida*1, V. Bosó2, M. Aguas1, S. Bejar1, A. Garrido1, M. Iborra1, J. del Hoyo1, L. Tortosa1, D. Muñoz1, R. Marqués2, J. L. Poveda2, P. Nos1

1Hospital Universitario y Politécnico La Fe, Gastroenterology, Valencia, Spain, 2Hospital Universitario y Politécnico La Fe, Pharmacy, Valencia, Spain

P458: Effect of cognitive behavioural therapy on clinical disease course in adolescents and young adults with inflammatory bowel disease and subclinical anxiety and/or depression: results of a randomised trial

ECCO '19 Copenhagen

Year: 2019
Authors:

G. van den Brink1, L. Stapersma2, A. S. Bom1, D. Rizopolous3, J. van der Woude4, R. Stuyt5, D. Hendriks6, J. van der Burg6, R. Beukers7, T. Korpershoek7, S. Theuns7, E. Utens2,8,9, J. Escher*1

1Erasmus MC-Sophia Children’s Hospital, Paediatric Gastroenterology, Rotterdam, The Netherlands, 2Erasmus MC-Sophia Children’s Hospital, Department of Child and Adolescent Psychiatry/Psychology, Rotterdam, The Netherlands, 3Erasmus MC, Department of Biostatistics, Rotterdam, The Netherlands, 4Erasmus MC, Department of Gastroenterology, Rotterdam, The Netherlands, 5Haga Hospital, Department of Gastroenterology, The Hague, The Netherlands, 6Juliana Children’s Hospital, Department of Paediatrics, The Hague, The Netherlands, 7Albert Schweitzer Hospital, Department of Paediatrics, Dordrecht, The Netherlands, 8University of Amsterdam, Research Institute of Child Development and Education, Amsterdam, The Netherlands, 9Academic Center for Child Psychiatry the Bascule, Department of Child and Adolescent Psychiatry, Amsterdam, The Netherlands

P459: Vedolizumab for the treatment of chronic pouchitis: the Edinburgh experience

ECCO '19 Copenhagen

Year: 2019
Authors:

S. Cesano*1,2, G. R. Jones2, P. W. Jenkinson2, A. G. Shand2, C. W. Lees2, I. D. Arnott2, N. Plevris2

1University of Pavia, Pavia, Italy, 2The Edinburgh IBD Unit, Western General Hospital, Edinburgh, UK